Table 1.

Demographic and clinical characteristics of patients with Aβ(−)MCI and Aβ(+)MCI.

Variable	CNI	Aβ(−)MCI	Aβ(+)MCI	p-Value
				CNI vs. Aβ(−)MCI	CNI vs. Aβ(+)MCI
Total, n	9	12	11	-	-
Age (years)	73.2 ± 1.43	74.2 ± 5.67	74.6 ± 2.48	0.681	0.660
Female (%)	66.7 ± 0.17	91.7 ± 0.29	72.7 ± 0.14	0.164	0.783
Education (years)	9.78 ± 1.40	9.50 ± 5.20	9.46 ± 1.27	0.897	0.870
BMI (kg/m2)	25.2 ± 1.23	23.7 ± 3.28	23.1 ± 0.49	0.335	0.109
HR	74.6 ± 4.98	76.8 ± 6.45	74.2 ± 3.13	0.640	0.949
MMSE	27.3 ± 0.29	24.5 ± 3.03	24.0 ± 0.53	0.014 †	< 0.001 †
CDR-SB	1.22 ± 0.21	1.83 ± 0.69	2.41 ± 0.27	0.049 †	0.004 †
GDS	2.11 ± 0.11	2.75 ± 0.45	2.73 ± 0.14	0.002 †	0.003 †
Platelet Count (108/mL)	2.06 ± 0.12	2.29 ± 0.93	2.33 ± 0.28	0.483	0.450
Amyloid PET (SUVr)
Cingulate gyrus (L + R)	0.72 ± 0.02	0.69 ± 0.05	0.92 ± 0.03	0.254	< 0.001 †
Frontal lobe (L + R)	0.58 ± 0.01	0.56 ± 0.05	0.79 ± 0.03	0.245	< 0.001 †
Occipital lobe (L + R)	0.61 ± 0.02	0.60 ± 0.04	0.68 ± 0.01	0.535	0.009 †
Parietal lobe (L + R)	0.58 ± 0.01	0.56 ± 0.04	0.79 ± 0.03	0.255	< 0.001 †
Temporal lobe (L + R)	0.60 ± 0.01	0.58 ± 0.04	0.78 ± 0.04	0.226	< 0.001 †
Global (L + R)	0.59 ± 0.01	0.57 ± 0.04	0.76 ± 0.02	0.281	< 0.001 †
ApoE ε4 carrier (%)	0.00 ± 0.00	8.00 ± 0.28	54.4 ± 0.15	0.400	0.006 †
Fazekas Scale (WMH)	1.33 ± 0.20	1.50 ± 0.52	1.27 ± 0.18	0.470	0.783
VBM
Hippocampus (L)	0.40 ± 0.05	0.36 ± 0.05	0.37 ± 0.03	0.062	0.066
Hippocampus (R)	0.40 ± 0.03	0.36 ± 0.05	0.36 ± 0.02	0.063	0.018 †

Data are expressed as mean ± SEM (range). For statistical analysis, unpaired Student’s t-test was used. ^† p < 0.05: MCI group versus CNI group. CNI, cognitive normal individual; Aβ(−)MCI, Non-Alzheimer’s pathologic change with MCI; and Aβ(+)MCI, Alzheimer’s pathologic change with MCI.